Harris Marianne, Larsen Gerene, Montaner Julio S G
AIDS Research Programme, St Paul's Hospital, Providence Healthcare, Canada.
AIDS. 2008 Jun 19;22(10):1224-6. doi: 10.1097/QAD.0b013e328302f3b5.
Enfuvirtide has been a cornerstone of salvage therapy for multidrug-resistant HIV. Raltegravir provides another novel class option, with the advantages of easier administration and improved tolerability. Thirty-five adults electively replaced enfuvirtide with raltegravir while the rest of their regimen was unchanged. All maintained virologic suppression after a median of 7 months except one who experienced a transiently detectable viral load after 5 months. The new regimen was well tolerated with no apparent new drug-related adverse clinical or laboratory events.
恩夫韦肽一直是多药耐药HIV挽救治疗的基石。拉替拉韦提供了另一种新型选择，具有给药更简便、耐受性更好的优点。35名成年人选择性地将恩夫韦肽替换为拉替拉韦，而他们的其他治疗方案保持不变。除1人在5个月后出现短暂可检测到的病毒载量外，所有患者在中位7个月后均维持病毒学抑制。新方案耐受性良好，没有明显的与新药相关的不良临床或实验室事件。
